BIO Biome Australia Ltd ASX · Australia

Biome Australia (BIO) news

Distress · Aug 4, 2026

Bio-Rad starts restructuring plan with $80 to $90 million in pre-tax charges

Bio-Rad Laboratories said on August 4, 2026 that the plan includes position eliminations and facility closures worldwide and is expected to be substantially completed by the end of fiscal year 2027. Second-quarter net sales were $651.0 million.

Latest Biome Australia news

Feb 13, 2025Distress
Bio-Rad restructuring to cut about 5% of workforce, with $45 million to $50 million in costs
Bio-Rad began the plan on February 7, 2025 and expects it to be substantially completed by the end of fiscal 2025. The company also made a binding offer to buy Stilla Technologies.

Questions about Biome Australia

What is the ticker symbol of Biome Australia?

Biome Australia Ltd trades under the ticker BIO on ASX.

Where is Biome Australia listed?

Biome Australia Ltd is listed on ASX.

Which country or territory is Biome Australia listed under?

Our directory records Biome Australia Ltd under Australia.

What does Biome Australia do?

Our directory classifies Biome Australia Ltd as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Biome Australia?

The ISIN recorded for Biome Australia Ltd is AU0000184137.

Does aibio.space cover Biome Australia?

aibio.space lists Biome Australia Ltd among 2,820 public biotech companies and publishes its news here as stories appear.

What is the latest Biome Australia (BIO) stock news?

Our latest story on Biome Australia, dated Aug 4, 2026: "Bio-Rad starts restructuring plan with $80 to $90 million in pre-tax charges". Bio-Rad Laboratories said on August 4, 2026 that the plan includes position eliminations and facility closures worldwide and is expected to be substantially completed by the end of fiscal year 2027. Second-quarter net sales were $651.0 million. Source.

Is Biome Australia in financial distress?

Our latest distress story, dated Aug 4, 2026: "Bio-Rad starts restructuring plan with $80 to $90 million in pre-tax charges". Bio-Rad Laboratories said on August 4, 2026 that the plan includes position eliminations and facility closures worldwide and is expected to be substantially completed by the end of fiscal year 2027. Second-quarter net sales were $651.0 million. Source.

Which companies are similar to Biome Australia?

Companies in our directory listed in the same country and business area as Biome Australia: Acrux, Recce Pharmaceuticals, Calmer Co International, Tissue Repair, PYC Therapeutics, Noxopharm.

How can I follow Biome Australia (BIO) news?

Press Follow on this page to add Biome Australia to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming Biome Australia so far, in Distress.

Investor discussion: Biome Australia

Members talk about Biome Australia (BIO). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open ASX:BIO on TradingView.

Listing details

Biome Australia Ltd is a public biotech or pharmaceutical company listed on ASX under the ticker BIO, recorded under Australia. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company: Biome Australia Ltd
Ticker: BIO
Listing: ASX
Country or territory: Australia
Business scope: Pharmaceuticals: Major
ISIN: AU0000184137
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction